Role of autotransplantation in Hodgkin's disease. (Q40831558)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

review article

1 reference

title

Role of autotransplantation in Hodgkin's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference

Bierman PJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

Armitage JO

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

publication date

1 June 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

Hematology / Oncology Clinics of North America

29 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

591-611

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

29 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Bone marrow transplantation for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Is there an effective salvage therapy for advanced Hodgkin's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Dose: a critical factor in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas and solid tumors. A study of 23 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Autologous bone marrow transplantation for patients with poor-prognosis lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Factors affecting the outcome of autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Late relapse among patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Peripheral blood stem cell collection and use in Hodgkin's disease. Comparison with marrow in autologous transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Autologous Bone Marrow Transplantation Followed by Involved Field Radiotherapy in Patients with Relapsed or Refractory Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Allogeneic marrow transplantation for refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Autotransplantation in lymphoma: better therapy or healthier patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930233-8

7 January 2021

10.1016/S0889-8588(18)30233-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8344883%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference